search
Back to results

Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder

Primary Purpose

Tobacco Use, Smoking Cessation, Nicotine Dependence

Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ketamine Hydrochloride
Motivational enhancement therapy
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: 21 to 65 years old. Able to provide informed consent. Be a daily cigarette smoker with multiple unsuccessful previous quit attempts, and report a continued desire to quit smoking. Agree to abstain from smoking for the ketamine session from 1 hour before ketamine administration Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of ketamine administration. Exceptions include caffeine and nicotine. Subjects taking other psychotropic medications must be maintained on a stable dose for at least four weeks before study initiation. Be healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG) to verify normal QTc intervals. Subjects with normal blood pressure not on antihypertensive medications or medication controlled hypertension as defined baseline visit systolic blood pressure (SBP) <140 mmHg or a diastolic blood pressure (DBP) <90 mmHg. Exclusion Criteria: Women who are pregnant (positive pregnancy test) or nursing, or are not practicing an effective means of birth control which can include oral, implant, intrauterine device, or patch contraceptive methods as well as barrier contraceptive methods, history of surgery such as hysterectomy or tubal ligation, or abstinence Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders or current depression or bipolar disorder based on clinical interview. Subjects meeting DSM-5 criteria for current substance use disorder other than tobacco use disorder. Subjects with hypertension as defined by a baseline visit systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) >90 mmHg. A history of allergic or other adverse reaction to ketamine (or its excipients). Clinically significant physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma, aneurysmal disease, cardiovascular disease, or end-stage renal disease). Cardiovascular conditions: uncontrolled hypertension, angina, a clinically significant ECG abnormality (e.g., atrial fibrillation), TIA in the last 6 months, stroke, peripheral or pulmonary vascular disease Subjects who live greater than 20 miles from the study site and cannot arrange their own transportation will be excluded from the study. Subjects with clinically significant kidney or liver impairment. Have any current neurological illnesses including, but not limited to, seizure disorders, frequent migraines or on prophylaxis, multiple sclerosis, movement disorders, history of significant head trauma, or CNS tumor. Morbidly obese (BMI >40), or severely underweight as determined by medical examination.

Sites / Locations

  • Medical University of South CarolinaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment of tobacco use disorder with ketamine

Arm Description

Outcomes

Primary Outcome Measures

Feasibility of ketamine treatment for tobacco use disorder
The primary outcome of this study will be the feasibility of using ketamine-assisted treatment for smoking cessation, which will assess the number of people selected for randomization that complete the full treatment. This will help determine if the treatment of ketamine in tobacco use would be beneficial for further study.

Secondary Outcome Measures

Smoking cessation
Saliva cotinine levels will be collected prior to each ketamine session and at each follow up to detect smoking over approximately the past 6 days
Reduction in cigarettes smoked per day
Evaluate if there is reduction in cigarettes smoked per day via the self-reported time-line follow back

Full Information

First Posted
March 21, 2023
Last Updated
June 28, 2023
Sponsor
Medical University of South Carolina
search

1. Study Identification

Unique Protocol Identification Number
NCT05796791
Brief Title
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
Official Title
Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 2, 2023 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of South Carolina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for tobacco use disorder when delivered in conjunction with brief motivational enhancement therapy. Participants will receive ketamine assisted motivational enhancement therapy weekly for three weeks and there will be 2 follow up visits. All visits will also consist of questionnaires and saliva samples will be taken. The overall participation will last approximately 8 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use, Smoking Cessation, Nicotine Dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Pilot Study
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment of tobacco use disorder with ketamine
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Ketamine Hydrochloride
Intervention Description
IM ketamine given in weekly session for a total of 3 weeks
Intervention Type
Behavioral
Intervention Name(s)
Motivational enhancement therapy
Intervention Description
Brief motivational based therapy
Primary Outcome Measure Information:
Title
Feasibility of ketamine treatment for tobacco use disorder
Description
The primary outcome of this study will be the feasibility of using ketamine-assisted treatment for smoking cessation, which will assess the number of people selected for randomization that complete the full treatment. This will help determine if the treatment of ketamine in tobacco use would be beneficial for further study.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Smoking cessation
Description
Saliva cotinine levels will be collected prior to each ketamine session and at each follow up to detect smoking over approximately the past 6 days
Time Frame
Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8
Title
Reduction in cigarettes smoked per day
Description
Evaluate if there is reduction in cigarettes smoked per day via the self-reported time-line follow back
Time Frame
Baseline, Treatment week 1, 2, 3, and follow up week 4, and 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 21 to 65 years old. Able to provide informed consent. Be a daily cigarette smoker with multiple unsuccessful previous quit attempts, and report a continued desire to quit smoking. Agree to abstain from smoking for the ketamine session from 1 hour before ketamine administration Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of ketamine administration. Exceptions include caffeine and nicotine. Subjects taking other psychotropic medications must be maintained on a stable dose for at least four weeks before study initiation. Be healthy as determined by screening for medical problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG) to verify normal QTc intervals. Subjects with normal blood pressure not on antihypertensive medications or medication controlled hypertension as defined baseline visit systolic blood pressure (SBP) <140 mmHg or a diastolic blood pressure (DBP) <90 mmHg. Exclusion Criteria: Women who are pregnant (positive pregnancy test) or nursing, or are not practicing an effective means of birth control which can include oral, implant, intrauterine device, or patch contraceptive methods as well as barrier contraceptive methods, history of surgery such as hysterectomy or tubal ligation, or abstinence Subjects who meet DSM-5 criteria for current or history of psychotic spectrum disorders or current depression or bipolar disorder based on clinical interview. Subjects meeting DSM-5 criteria for current substance use disorder other than tobacco use disorder. Subjects with hypertension as defined by a baseline visit systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure (DBP) >90 mmHg. A history of allergic or other adverse reaction to ketamine (or its excipients). Clinically significant physical exam findings or self-reported medical conditions for which a transient increase in blood pressure could be significantly detrimental (e.g. glaucoma, aneurysmal disease, cardiovascular disease, or end-stage renal disease). Cardiovascular conditions: uncontrolled hypertension, angina, a clinically significant ECG abnormality (e.g., atrial fibrillation), TIA in the last 6 months, stroke, peripheral or pulmonary vascular disease Subjects who live greater than 20 miles from the study site and cannot arrange their own transportation will be excluded from the study. Subjects with clinically significant kidney or liver impairment. Have any current neurological illnesses including, but not limited to, seizure disorders, frequent migraines or on prophylaxis, multiple sclerosis, movement disorders, history of significant head trauma, or CNS tumor. Morbidly obese (BMI >40), or severely underweight as determined by medical examination.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Emily C Amador, DO
Phone
843-608-1216
Email
amador@musc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Jones, MD
Email
jonjen@musc.edu
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29412
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Amador, D.O.
Phone
651-387-9787
Email
amador@musc.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder

We'll reach out to this number within 24 hrs